Fulcrum Therapeutics Overview
Fulcrum Therapeutics Target Price
Analysts' 12-month price predictions for FULC.
Share Price
$6.8
Average Target Price
$10.50
54.4% upside
54.4% upside2 analysts in the last 4 months
High: $12 | Low: $9
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-05-29 | Piper SandlerEdward Tenthoff | $9 | 32.4% upside |  |
| 2025-05-23 | Leerink PartnersJoseph Schwartz | $12 | 76.5% upside | |
| 2024-09-13 | H.C. WainwrightAndrew Fein | $4 |  41.2% downside | |
| 2024-09-12 | RBC CapitalGregory Renza | $4 | 41.2% downside | |
| 2024-09-12 | Stifel NicolausDae Gon Ha downgraded Fulcrum Therapeutics | $3 | 55.9% downside | |
| 2024-09-12 | Bank of America SecuritiesTazeen Ahmad | $2 | 70.6% downside | |
| 2024-09-09 | Bank of America SecuritiesTazeen Ahmad | $10 | 47.1% upside | |
| 2024-09-03 | RBC CapitalGregory Renza | $15 | 120.6% upside | |
| 2024-05-20 | Cantor FitzgeraldKristen Kluska | $23 | 238.2% upside | |
| 2024-05-13 | Goldman SachsCorinne Jenkins | $15 | 120.6% upside | |
| 2024-05-13 | Stifel NicolausDae Gon Ha | $22 | 223.5% upside | |
| 2024-03-13 | RBC CapitalGregory Renza | $14 | 105.9% upside | |
| 2022-11-15 | Goldman Sachs | $11 | 61.8% upside | |
| 2022-11-08 | Piper SandlerEdward Tenthoff | $18 | 164.7% upside | |